Shortt, Jake
Ott, Christopher J.
Johnstone, Ricky W.
Bradner, James E.
Article History
First Online: 23 February 2017
Change Date: 10 March 2017
Change Type: Corrigendum
Change Details: Supplementary information S1-S6 (tables) for this article have been replaced, with several minor errors in the tables and references corrected.
Competing interests
: R.W.J. has received research grants and honorarium from Novartis, Astra-Zeneca, AbbVie and Roche. J.S. has received speakers' bureaux/honoraria from Bristol-Myers Squibb (BMS), Celgene and Novartis, travel sponsorships from BMS and Novartis, and research funding from BMS. J.E.B. is a founder of Tensha Therapeutics, a biotechnology company that develops drug-like derivatives of JQ1 as investigational cancer therapies and is a current employee of Novartis.